# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0000000000-26-000815
**Filing Date:** 2026-1
**Character Count:** 2442
**Document Hash:** 854da86d5cee0bfa094a7b0fa252e2e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-000815.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0000000000-26-000815

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260127

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292930

**BUSINESS ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602
- **BUSINESS PHONE:** (929) 274-7510

**MAIL ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-26-003458

## Text-Extract

```

                                                           January 27, 2026

Abizer Gaslightwala
Chief Executive Officer
Akari Therapeutics, Plc
401 East Jackson St, Suite 3300
Tampa, FL 33602

       Re: Akari Therapeutics, Plc
           Registration Statement on Form S-1
           Filed January 23, 2026
           File No. 333-292930
Dear Abizer Gaslightwala:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Doris Stacey Gama at 202-551-3188 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Win Rutherfurd, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._